Malaria Research and Treatment / 2013 / Article / Tab 2

Clinical Study

Amodiaquine-Artesunate versus Artemether-Lumefantrine against Uncomplicated Malaria in Children Less Than 14 Years in Ngaoundere, North Cameroon: Efficacy, Safety, and Baseline Drug Resistant Mutations in pfcrt, pfmdr1, and pfdhfr Genes

Table 2

Crude and PCR adjusted days 14 and 28 treatment outcomes of study participants on AS/AQ or AL.

Efficacy outcomeAS/AQAL
% %

Crude day 14 cure rates6869
 ACPR6189.76797.1
 ETF0202.900
 LCF0101.500
 LPF0406.00203.0
Crude day 28 cure rates6164
 ACPR5488.56296.9
 ETF0203.300
 LCF0101.600
 LPF0406.60203.1
PCR corrected day 28 cure rates 5662
 ACPR5496.462100
 ETF0203.600
 LCF0000
 LPF0000

Note: Reinfections were excluded from the analysis after profiling pretreatment and recurrent parasites based on the polymorphic Plasmodium falciparum  msp  2 antigen. ACPR: adequate clinical parasitological response, ETF: early treatment failure, LCF: late clinical failure, LPF: late parasitological failure, and CI: confidence interval. Early treatment failures were noted in two patients randomized to receive ASAQ coblister. It was unclear if this was due to poor drug absorption or real treatment failures.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.